Trial Profile
A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sapropterin (Primary)
- Indications Phenylketonuria
- Focus Registrational; Therapeutic Use
- Sponsors BioMarin Pharmaceutical
- 22 Jan 2019 Status changed from active, no longer recruiting to completed.
- 10 Jan 2017 Planned End Date changed from 1 Dec 2018 to 1 Jan 2020.
- 10 Jan 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Aug 2019.